Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of E-SYNC T Cells in EGFRvIII+ Glioblastoma
NCT06186401Phase 1Recruiting
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of E-SYNC T Cells in glioblastoma (GBM) (3 cohorts). Primary endpoint: Proportion of participants reporting treatment-emergent adverse events at 96 weeks. Started Apr 2024; status: recruiting.
02
Drugs
E-SYNC T Cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06186401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186401.